MTOR and acute myeloid leukemia: The PI3K-Akt-mTOR pathway shows constitutive activation in human AML and is therefore regarded as a possible therapeutic target, but despite this, the results from initial clinical studies suggest that pathway inhibitors have only modest antileukemic activity [13].